https://european-biotechnology.net/wp-content/uploads/2025/04/fab8ad76-cf6e-4e34-a523-324dc0865c50-e1745917221177-1030x579-1.webp5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-04-29 09:18:592025-04-29 09:18:59Yeast on the Final Frontier
https://european-biotechnology.net/wp-content/uploads/2025/04/CY-101-MOA-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-04-24 06:39:042025-04-24 06:39:04Cytovation ASA bags additional US$6m to drive Phase II study
https://european-biotechnology.net/wp-content/uploads/2025/04/aktie.traderfox.png379948Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-04-23 13:24:162025-04-23 13:24:16KKR makes US$1.22bn tender for Swedish Biotage AB
https://european-biotechnology.net/wp-content/uploads/2025/04/pharma-tariffs_1000_F_127114908_Af4TT80EpqcXxWWKOylZ84ms69Y1zgl0.jpg5361000Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-04-23 10:53:452025-04-23 13:32:03Roche and Novartis react to US tariffs
